...
首页> 外文期刊>BMC Infectious Diseases >Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non- albicans Candida species
【24h】

Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non- albicans Candida species

机译:念珠菌和非蛋白质念珠菌念珠菌患者侵袭性念珠菌初级治疗抗真菌疗法的药物经济分析

获取原文

摘要

Background Cost-effectiveness studies of echinocandins for the treatment of invasive candidiasis, including candidemia, are rare in Asia. No study has determined whether echinocandins are cost-effective for both Candida albicans and non- albicans Candida species. There have been no economic evaluations that compare non-echinocandins with the three available echinocandins. This study was aimed to assess the cost-effectiveness of individual echinocandins, namely caspofungin, micafungin, and anidulafungin, versus non-echinocandins for C. albicans and non- albicans Candida species, respectively. Methods A decision tree model was constructed to assess the cost-effectiveness of echinocandins and non-echinocandins for invasive candidiasis. The probability of treatment success, mortality rate, and adverse drug events were extracted from published clinical trials. The cost variables (i.e., drug acquisition) were based on Taiwan’s healthcare system from the perspective of a medical payer. One-way sensitivity analyses and probability sensitivity analyses were conducted. Results For treating invasive candidiasis (all species), as compared to fluconazole, micafungin and caspofungin are dominated (less effective, more expensive), whereas anidulafungin is cost-effective (more effective, more expensive), costing US$3666.09 for each life-year gained, which was below the implicit threshold of the incremental cost-effectiveness ratio in Taiwan. For C. albicans , echinocandins are cost-saving as compared to non-echinocandins. For non- albicans Candida species, echinocandins are cost-effective as compared to non-echinocandins, costing US$652 for each life-year gained. The results were robust over a wide range of sensitivity analyses and were most sensitive to the clinical efficacy of antifungal treatment. Conclusions Echinocandins, especially anidulafungin, appear to be cost-effective for invasive candidiasis caused by C. albicans and non- albicans Candida species in Taiwan.
机译:背景技术echinocandins治疗侵袭性念珠菌病的成本效果研究,包括念珠菌症,在亚洲都很罕见。没有研究确定Echinocandins是否对念珠菌蛋白和非白醛念珠菌念珠菌物种具有成本效益。没有经济评估,比较非埃希纳西亚与三种可用的echinocandins。本研究旨在评估个体echinocandins,即Caspofungin,Micafungin和Anidulafungin的成本效益,分别与蛋白质和非醛糖蛋白念珠菌的非echinocandins分别。方法构建决策树模型以评估侵入性念珠菌病的echinocandins和非呼吸皂苷酸的成本效果。从公开的临床试验中提取治疗成功,死亡率和不良药物事件的可能性。成本变量(即,药物收购)从医疗付款人的角度来基于台湾的医疗保健系统。进行单向敏感性分析和概率敏感性分析。与氟康唑相比,治疗侵袭性念珠菌病(所有物种),Micafungin和Caspofungin占主导地位(较低效率,更昂贵),而Anidulafungin则具有成本效益(更有效,更昂贵),每年的生长时间为3666.09美元获得,低于台湾增量成本效益比的隐含阈值。对于白醛,与非呼吸植物相比,Echinocandins是节省成本节省的。对于非白名单念珠菌物种,与非埃希奥纳的抗议生素相比,Echinocandins具有成本效益,每年获得每年的生命年份为652美元。结果在广泛的敏感性分析方面具有稳健性,对抗真菌治疗的临床疗效最敏感。结论Echinocandins,尤其是Anidulafungin,对于由台湾的C. albicans和非蛋白质人念珠菌物种引起的侵袭性念珠菌病是成本效益的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号